

# A NEW FRONTIER IN CANCER THERAPY

## Examining the Role of PARP Inhibitors in an Emerging Paradigm

American Society of Clinical Oncology. American Society of Clinical Oncology Statement on the impact of utilization management policies for cancer drug therapies. *J Oncol Pract.* 2017;13(11):758–762.

Brett J, Fenlon D, Boulton M, et al. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer. *Eur J Cancer Care (Engl).* 2018;27(1).

Cass Y, Connor TH, Tabachnik K. Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home setting. *J Oncol Pharm Pract.* 2017;23(5):350–378.

Cervelli T, Borghini A, Galli A, et al. DNA damage and repair in atherosclerosis: current insights and future perspectives. *Int J Mol Sci.* 2012;13(12):16929–16944.

Coleman RL, Oza AM, Lorusso D, et al. ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase III trial [published correction appears in: *Lancet.* 2017;390(10106):1948]. *Lancet.* 2017;390(10106):1949–1961.

Drugs@FDA. FDA approved drug products: olaparib. U.S. Food and Drug Administration website. December 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/208558s006lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf). Accessed March 2019.

Drugs@FDA. FDA approved drug products: niraparib. U.S. Food and Drug Administration website. March 2017. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2017/208447lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf). Accessed March 2019.

Drugs@FDA. FDA approved drug products: rucaparib. U.S. Food and Drug Administration website. April 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/209115s003lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf). Accessed March 2019.

Drugs@FDA. FDA approved drug products: talazoparib. U.S. Food and Drug Administration website. October 2018. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/211651s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf). Accessed March 2019.

Economic impact of cancer. American Cancer Society website. January 3, 2018. <https://www.cancer.org/cancer/cancer-basics/economic-impact-of-cancer.html>. Accessed March 2019.

FDA approves olaparib for germline *BRCA*-mutated metastatic breast cancer. U.S. Food and Drug Administration website. January 12, 2018. <https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm592357.htm>. Accessed March 2019.

FDA approves olaparib for first-line maintenance of *BRCA*-mutated advanced ovarian cancer. U.S. Food and Drug Administration website. December 19, 2018. <https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm628876.htm>. Accessed March 2019.

FDA approves olaparib tablets for maintenance treatment in ovarian cancer. U.S. Food and Drug Administration website. August 17, 2017. <https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm572143.htm>. Accessed March 2019.

FDA approves talazoparib for g*BRCA*Am HER2-negative locally advanced or metastatic breast cancer. U.S. Food and Drug Administration website. October 16, 2018. <https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm623540.htm>. Accessed March 2019.

Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centered outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a *BRCA1/2* mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase III randomised trial. *Lancet Oncol.* 2018;19(8):1126–1134.

# A NEW FRONTIER IN CANCER THERAPY

- Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. *Am J Hematol.* 2011;86(6):471–474.
- Genetics toolkit. American Society of Clinical Oncology website. December 2018. <https://www.asco.org/practice-guidelines/cancer-care-initiatives/genetics-toolkit/assessing-your-patient%E2%80%99s-hereditary>. Accessed March 2019.
- Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. *Oncologist.* 2016;21(3):354–376.
- Helleday T. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline *BRCA* mutations. *Ann Oncol.* 2016;27(5):755–757.
- Hernandez R. Partial-fill strategies: do they work? Specialty Pharmacy Times website. November 8, 2013. <https://www.specialtypharmacytimes.com/news/partial-fill-strategies-do-they-work>. Accessed March 2019.
- Iglehart JD, Silver DP. Synthetic lethality—a new direction in cancer drug development. *N Engl J Med.* 2009;361(2):189–191.
- Kaddis AA. Partial fill strategies for oral oncolytics to reduce waste and drive persistency. *Am J Manag Care.* 2013;19(1):SP26–SP27.
- Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline *BRCA1/2* mutation. *J Clin Oncol.* 2015;33(3):244–250.
- Kavookjian J, Wittayanukorn S. Interventions for adherence with oral chemotherapy in hematological malignancies: a systematic review. *Res Social Adm Pharm.* 2015;11(3):303–314.
- Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. *Cancer Discov.* 2015;5(11):1137–1154.
- Lester J. Safe handling and administration considerations of oral anticancer agents in the clinical and home setting. *Clin J Oncol Nurs.* 2012;16(6):E192–E197.
- List of cleared or approved companion diagnostic devices (in vitro and imaging tools). U.S. Food and Drug Administration website. December 13, 2018. <https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm>. Accessed March 2019.
- Litton JK, Rugo HS, Ettl J, et al. EMBRACA: a phase III trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline *BRCA* mutation. *Cancer Res.* 2018;78:GS6-07.
- Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline *BRCA* mutation. *N Engl J Med.* 2018;379(8):753–763.
- Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. *Science.* 2017;355(6330):1152–1158.
- Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020 [published correction appears in: *J Natl Cancer Inst.* 2011;103(8):699]. *J Natl Cancer Inst.* 2011;103(2):117–128.
- Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. *N Engl J Med.* 2015;373(18):1697–1708.
- Mateo J, Moreno V, Gupta A, et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. *Target Oncol.* 2016;11(3):401–415.
- McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. *Br J Cancer.* 2008;99(11):1763–1768.

# A NEW FRONTIER IN CANCER THERAPY

- Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *N Engl J Med.* 2016;375(22):2154–2164.
- Murai J, Huang SY, Das BB, et al. Differential trapping of PARP1 and PARP2 by clinical PARP Inhibitors. *Cancer Res.* 2012;72(21):5588–5599.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Ovarian Cancer. NCCN website. Version1.2019, March 8, 2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/ovarian.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf). Accessed March 2019.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Antiemesis. NCCN website. Version 1.2019, February 28, 2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/antiemesis.pdf](https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf). Accessed March 2019.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast cancer. NCCN website. Version 4.2018, February 8, 2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed March 2019.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cancer-related fatigue. NCCN website. Version 2.2018, February 20, 2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/fatigue.pdf](https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf). Accessed March 2019.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian. NCCN website. Version 3.2019, January 18, 2019. [https://www.nccn.org/professionals/physician\\_gls/pdf/genetics\\_screening.pdf](https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf). Accessed March 2019.
- National prescription drug take-back day. U.S Drug Enforcement Administration website. [https://www.deadiversion.usdoj.gov/drug\\_disposal/takeback/index.html](https://www.deadiversion.usdoj.gov/drug_disposal/takeback/index.html). Accessed March 2019.
- Neuss MN, Gilmore TR, Belderson KM, et al. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. *Oncol Nurs Forum.* 2017;44(1):31–43.
- NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016. Centers for Disease Control and Prevention website. September 2016. <https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf?id=10.26616/NIOSHPUB2016161>. Accessed March 2019.
- Oza AM, Matulonis UA, Malander S, et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase III, randomised controlled trial. *Lancet Oncol.* 2018;19(8):1117–1125.
- Partridge AH, Avorn J, Wang PS, et al. Adherence to therapy with oral antineoplastic agents. *J Natl Cancer Inst.* 2002;94(9):652–661.
- Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. *Gynecol Oncol.* 2012;124(2):347–353.
- Pommier Y, O'Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action [published correction appears in: *Sci Transl Med.* 2016;8(368):368er7]. *Sci Transl Med.* 2016;8(362):362ps17.
- Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline *BRCA* mutation. *N Engl J Med.* 2017;377(6):523–533.
- Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline *BRCA* mutation and HER2-negative metastatic breast cancer. *Ann Oncol.* January 23, 2019. [Epub ahead of print.]

# A NEW FRONTIER IN CANCER THERAPY

- Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. *J Clin Oncol.* 2015;33(31):3660–3667.
- Rucaparib. U.S. Food and Drug Administration website. December 19, 2016.  
<https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm533891.htm>. Accessed March 2019.
- Salgado TM, Mackler E, Severson JA, et al. The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices. *Support Care Cancer.* 2017;25(6):1797–1807.
- SGO clinical practice statement: genetic testing for ovarian cancer. Society of Gynecologic Oncology website. October 2014. <https://www.sgo.org/clinical-practice/guidelines/genetic-testing-for-ovarian-cancer/>. Accessed March 2019.
- Schell S. Identifying best practices in cancer care management. Managed Care website. September 23, 2013.  
<https://www.managedcaremag.com/archives/2013/9/identifying-best-practices-cancer-care-management>. Accessed March 2019.
- Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase II trial. *Lancet Oncol.* 2017;18(1):75–87.
- Understanding the costs related to cancer. Cancer.Net website. March 2018. <https://www.cancer.net/navigating-cancer-care/financial-considerations/understanding-costs-related-cancer-care>. Accessed March 2019.
- U.S. National Library of Medicine. ClinicalTrials.gov. <https://clinicaltrials.gov/>. Accessed March 2019.
- Weingart SN, Brown E, Bach PB, et al. NCCN task force report: oral chemotherapy. *J Natl Compr Canc Netw.* 2008;6 Suppl 3:S1–S14.
- Weingart SN, Toro J, Spencer J, et al. Medication errors involving oral chemotherapy. *Cancer.* 2010;116(10):2455–2464.
- Wong SF, Bounthavong M, Nguyen C, et al. Implementation and preliminary outcomes of a comprehensive oral chemotherapy management clinic. *Am J Health Syst Pharm.* 2014;71(11):960–965.
- Yang J, Neugut AI, Wright JD, et al. Nonadherence to oral medications for chronic conditions in breast cancer survivors. *J Oncol Pract.* 2016;12(8):e800–e809.
- Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. *Drug Des Devel Ther.* 2017;11:3009–3017.